Enzon Pharmaceuticals, Inc. (ENZN)
A biopharmaceutical company dedicated to the development and commercialization of therapeutics to treat patients with cancer and adjacent diseases.
Recs
This biotech has a reliable royalty revenue stream from its proprietary pegylation technology which makes drugs less toxic, and more effective. It has a solid balance sheet and some interesting compounds in the pipeline. It has just sold off a portfolio of drugs to fix the balance sheet. Undervalued due to years of questionable decisions by management, the new CEO has now put the house in order, which promises appreciation to fair value and more gains if one of the drugs in the pipeline pans out.
Recs
UL predicting a buyout by wellpoint
Recs
it has a unique drug delivery system and activist shareholders
Recs
An Icahn portfolio stock.
Recs
I like the sector. This is a sector pick as I have done little DD on this stock. I think small biotech has been hit hard, and the cancer market, in particular, is going to turn around. Plus, I do not see too many incredible investments in other sectors so I am sticking to high risk/ high reward opportunities.
Recs
Working on 2 cancer drugs and will be the big winner!!
Recs
People all ways needing pills so Pharmaceuticals all ways geting business and all ways will
Recs
PEG-SN38 showed anti-tumor activity in resistant pre-clinical models, FDA approval for DepoCyt, leader in stem cell research, I can see it doing phenomenal
Recs
low PE & a good choice for a play in this sector
Recs
NICE PIPELINE
Recs
New cancer treatment
Recs
All looks bad for it but ....just a feeling

RSS Headlines
Fool UK
- Show Me:
-
Outperform
-
Underperform
-
All
- Sort by:
-
Author
-
Recs
-
Date
-
Member Rating
-
Results 1 - 12 of 12